Results of this study provide evidence that some miR-425-5p targeted genes are involved in EGFR tyrosine kinase inhibitor resistance pathway, suggesting that miR-425-5p-based therapies might have a strong potential in targeting KRAS-driven CRC. The gene discussed is EGFR; the disease is colorectal carcinoma.